Baseline characteristics
| Group A (n=43) | Group B (n=77) | P value | |
| Variable | |||
| Age at implantation, years | 51±18 | 44±15 | 0.05 |
| Male sex | 20 (47%) | 39 (51%) | 0.66 |
| Inherited cardiomyopathy | 12 (28%) | 25 (32%) | 0.60 |
| Congenital heart disease | 7 (16%) | 27 (35%) | 0.03 |
| Channelopathy | 12 (28%) | 16 (21%) | 0.38 |
| Other structural heart disease | 12 (28%) | 9 (12%) | 0.03 |
| Family history of SCD | 8 (19%) | 7 (9%) | 0.13 |
| Atrial fibrillation | 4 (9%) | 10 (13%) | 0.55 |
| Diabetes mellitus | 1 (2%) | 6 (8%) | 0.42 |
| Renal insufficiency | 1 (2%) | 1 (1%) | 0.59 |
| Systemic systolic ventricular function | |||
| Moderate dysfunction, 35%–45% | 6 (14%) | 6 (8%) | 0.35 |
| Mild dysfunction, 45%–55% | 10 (23%) | 19 (25%) | 0.86 |
| Normal, >55% | 27 (61%) | 52 (67%) | 0.60 |
| Patients with Holter | 37 (84%) | 76 (98%) | <0.01 |
| NSVT on Holter | 7 (16%) | 29 (38%) | 0.01 |
| Medication | |||
| AAD | 21 (49%) | 44 (57%) | 0.38 |
| Betablocker | 18 (85%) | 37 (84%) | 0.51 |
| Sotalol | 2 (10%) | 5 (11%) | 0.51 |
| Verapamil/diltiazem | 2 (10%) | 2 (5%) | 0.62 |
| AAD class I | 1 (5%) | 1 (2%) | 0.59 |
| Amiodaron | – | 1 (2%) | 0.36 |
| Oral anticoagulation | 6 (14%) | 13 (17%) | 0.67 |
Data are presented as n (%) or mean±SD.
AAD, antiarrhythmic drugs; ILR, implantable loop recorder; LVEF, left ventricular ejection fraction; NSVT, non-sustained ventricular tachycardia; SCD, sudden cardiac death.